Join Growin Stock Community!

寶島科5312.TW Overview

TW StockBiotech. & Medical
(No presentation for 5312)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

寶島科(5312)Overall Performance

寶島科(5312)AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

寶島科(5312) PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

寶島科(5312)Key Information

寶島科(5312)Profile

Formosa Optical Technology Co.,Ltd. provides eyecare products in Taiwan. The company offers optical glasses, sunglasses, contact transparent lenses, and color contact lenses. It also provides optometry equipment. The company was founded in 1976 and is based in New Taipei City, Taiwan.

寶島科(5312)FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
64.06%
Net Margin
10.47%
Revenue Growth (YoY)
-0.54%
Profit Growth (YoY)
3.24%
3-Year Revenue Growth
13.28%
3-Year Profit Growth
14.91%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
64.06%
Net Margin
10.47%
Revenue Growth (YoY)
-0.54%
Profit Growth (YoY)
3.24%
3-Year Revenue Growth
13.28%
3-Year Profit Growth
14.91%
default symbol

5312

寶島科

98.90D

-0.71%

(-0.01)

  • When is 5312's latest earnings report released?

    The most recent financial report for 寶島科 (5312) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 5312's short-term business performance and financial health. For the latest updates on 5312's earnings releases, visit this page regularly.

  • Where does 5312 fall in the P/E River chart?

    According to historical valuation range analysis, 寶島科 (5312)'s current price-to-earnings (P/E) ratio is 10.8, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of 5312?

    According to the latest financial report, 寶島科 (5312) reported an Operating Profit of 73.24M with an Operating Margin of 7.04% this period, representing a decline of 1.45% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 5312's revenue growth?

    In the latest financial report, 寶島科 (5312) announced revenue of 1.04B, with a Year-Over-Year growth rate of 2.67%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 5312 have?

    At the end of the period, 寶島科 (5312) held Total Cash and Cash Equivalents of 239.76M, accounting for 0.03 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 5312 go with three margins increasing?

    In the latest report, 寶島科 (5312) achieved the “three margins increasing” benchmark, with a gross margin of 63.81%%, operating margin of 7.04%%, and net margin of 14.98%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 5312's profit trajectory and future growth potential.

  • Is 5312's EPS continuing to grow?

    According to the past four quarterly reports, 寶島科 (5312)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 2.6. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 5312?

    寶島科 (5312)'s Free Cash Flow (FCF) for the period is -100.07M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 149.42% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.